|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 6
2022
Francis, K. E.; Kim, S. I.; Friedlander, M.; Gebski, V.; Ray-Coquard, I.; Clamp, A.; Penson, R. T.; Oza, A.; Perri, T.; Huzarski, T.; Martin-Lorente, C.; Cecere, S. C.; Colombo, N.; Ataseven, B.; Fujiwara, K.; Sonke, G.; Vergote, I.; Pujade-Lauraine, E.; Kim, J.-W. und Lee, C. K.
(2022):
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
In: Annals of Oncology, Bd. 33, Nr. 6: S. 593-601
2019
Ray-Coquard, I.; Trama, Annalisa; Seckl, M. J.; Fotopoulou, C.; Pautier, P.; Pignata, S.; Kristensen, G.; Mangili, G.; Falconer, H.; Massuger, L.; Sehouli, J.; Pujade-Lauraine, E.; Lorusso, D.; Amant, F.; Rokkones, E.; Vergote, I.; Ledermann, J. A. und Schubert-Fritschle, Gabriele
(Januar 2019):
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
In: European Journal of Surgical Oncology, Bd. 45, Nr. 1: S. 67-74
Ray-Coquard, I.; Pautier, P.; Pignata, S.; Perol, D.; Gonzalez-Martin, A.; Berger, R.; Fujiwara, K.; Vergote, I.; Colombo, N.; Maenpaa, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Alia, E. M. Guerra; Reinthaller, A.; Nagao, S.; Lefeuvre-Plesse, C.; Canzler, U.; Scambia, G.; Lortholary, A.; Marme, F.; Combe, P.; de Gregorio, N.; Rodrigues, M.; Buderath, P.; Dubot, C.; Burges, A.; You, B.; Pujade-Lauraine, E. und Harter, P.
(2019):
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
In: New England Journal of Medicine, Bd. 381, Nr. 25: S. 2416-2428
2016
Trillsch, F.; Mahner, S.; Hilpert, F.; Davies, L.; García-Martínez, E.; Kristensen, G.; Savarese, A.; Vuylsteke, P.; Los, M.; Zagouri, F.; Gladieff, L.; Sehouli, J.; Lee, C. Khoon; Gebski, V. und Pujade-Lauraine, E.
(2016):
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1733-1739
Lindemann, K.; Kristensen, G.; Mirza, M. R.; Davies, L.; Hilpert, F.; Romero, I.; Ayhan, A.; Burges, A.; Rubio, M. J.; Raspagliesi, F.; Huizing, M.; Creemers, G.-J.; Lykka, M.; Lee, C. K.; Gebski, V. und Pujade-Lauraine, E.
(2016):
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1505-1510
Trillsch, F.; Mahner, S.; Hilpert, F.; Davis, L.; Garcia, E.; Kristensen, G.; Savarese, A.; Vuylsteke, P.; Loos, M.; Zagouri, F.; Gladieff, L.; Sehouli, J.; Lee, C. K.; Gebski, V. und Pujade-Lauraine, E.
(2016):
Prognostic and predictive values of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.
In: Oncology Research and Treatment, Bd. 39: S. 93